Hsbc Holdings PLC Celldex Therapeutics, Inc. Transaction History
Hsbc Holdings PLC
- $176 Billion
- Q3 2025
A detailed history of Hsbc Holdings PLC transactions in Celldex Therapeutics, Inc. stock. As of the latest transaction made, Hsbc Holdings PLC holds 8,145 shares of CLDX stock, worth $208,104. This represents 0.0% of its overall portfolio holdings.
Number of Shares
8,145
Previous 17,579
53.67%
Holding current value
$208,104
Previous $357,000
41.18%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding CLDX
# of Institutions
204Shares Held
66.8MCall Options Held
222KPut Options Held
234K-
Kynam Capital Management, LP Princeton, NJ6.1MShares$156 Million13.34% of portfolio
-
Wellington Management Group LLP Boston, MA5.8MShares$148 Million0.03% of portfolio
-
Black Rock Inc. New York, NY4.69MShares$120 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.95MShares$101 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct3.89MShares$99.5 Million0.2% of portfolio
About Celldex Therapeutics, Inc.
- Ticker CLDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,772,400
- Market Cap $1.2B
- Description
- Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...